|
Wednesday, November 14, 2007
Ambit Biosciences Gets $49M In Funding
San Diego-based Ambit Biosciences said today that it has raised $49.3M in a Series D equity financing. According to Ambit, the round came from Apposite Capital LLP, and also included MedImmune Ventures, OrbiMed Advisors, Radius Ventures, NovaQuest, and Horizon Technology Finance, along with existing investors Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Avalon Ventures, Roche Venture Fund, GIMV, Jov-CMDF, and Genechem. The firm said the funding will go towards advancing its product pipeline. Ambit is focused on developing small molecule kinase inhibitors for the treatment of cancer.
posted on Wednesday, November 14, 2007 (Link to more information)
|
 RSS
 Email
Twitter
Previous news:
Thursday, November 20, 2008
Wednesday, November 19, 2008
Tuesday, November 18, 2008
Monday, November 17, 2008
Friday, November 14, 2008
|
